[Pharmacological and clinical profiles of a human GLP-1 analogue, liraglutide (Victoza(®))].
Sugii
Hiroshi
H
hsgi@novonordisk.com
Matsumura
Yoriko
Y
Inoue
Akihiro
A
Horigome
Hiroaki
H
Matsuzaki
Katsuhiro
K
Shimizu
Akane
A
D000818:Animals; D001786:Blood Glucose / Q000187:drug effects; D002273:Carcinogens; D002478:Cells, Cultured; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D050417:Insulin-Secreting Cells / Q000187:drug effects; D000069450:Liraglutide; D051379:Mice; D051381:Rats
D001786:Blood Glucose; D002273:Carcinogens; D007004:Hypoglycemic Agents; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1